For Patients Full Prescribing Information With Medication Guide IFU Important Safety Information Contact a Representative

SUSTOL—robust safety profile in clinical studies involving >2400 patients^1-3

Adverse reactions in ≥3% in SUSTOL-treated patients during two trials. SUSTOL had no significant effect on any electrocardiogram interval in clinical trials

Most side effects seen with SUSTOL are consistent with what is expected of 5-HT₃ RAs^4,6-10
SUSTOL had no significant effect on any electrocardiogram interval, including QTc duration, in clinical trials⁴

Due to the unique polymer delivery system of SUSTOL, injection site reactions (ISRs) are expected but generally manageable^4,5

Injection site reactions (ISRs) following a single 10 mg SUSTOL dose. Fewer than 1% of patients discontinued treatment due to ISRs

Three percent of patients receiving SUSTOL reported severe ISRs¹¹
- Fewer than 1% of patients discontinued treatment due to ISRs
- Frequency and severity of most ISRs decreased in subsequent cycles

All reactions occurring at ≥3% in the SUSTOL group.⁴
Modified Absorption of Granisetron In the Prevention of CINV.¹²
The placebo subcutaneous injection for Study 1 was normal saline; for Study 2 it was a SUSTOL-matched control (the polymer vehicle without active drug).⁴
All groups received dexamethasone.⁴

5-HT₃ RA=5-hydroxytryptamine 3 receptor antagonist; IV=intravenous; QTc=corrected QT interval.

Engineered to last with
extended-release technology⁴

See how the polymer works

How SUSTOL is supplied and administered

$0 copay for eligible patients, broad support for your practice

Learn about Heron Connect^®

INDICATION

SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

IMPORTANT SAFETY INFORMATION

Contraindications

SUSTOL is contraindicated in patients with hypersensitivity to granisetron, any of the components of SUSTOL, or any other 5-HT₃ receptor antagonist.

Warnings and Precautions

Injection site reactions (ISRs), including infection, bleeding, pain and tenderness, nodules, swelling, and induration, have occurred with SUSTOL. Monitor for ISRs following SUSTOL injection. Inform patients that some ISRs may occur 2 weeks or more after SUSTOL administration. In patients receiving antiplatelet agents or anticoagulants, consider the increased risk of bruising or severe hematoma prior to the use of SUSTOL.

Monitor for constipation and decreased bowel activity and consider optimizing patients’ current bowel regimens used for managing preexisting constipation. Instruct patients to seek immediate medical care if signs and symptoms of ileus occur.

Hypersensitivity reactions have been reported and may occur up to 7 days or longer following SUSTOL administration and may have an extended course. If a reaction occurs, administer appropriate treatment and monitor until signs and symptoms resolve.

Serotonin syndrome has been reported with 5-HT₃ receptor antagonists alone but particularly with concomitant use of serotonergic drugs.

Use in Specific Populations

Avoid SUSTOL in patients with severe renal impairment. In patients with moderate renal impairment, administer SUSTOL not more frequently than once every 14 days.

Adverse Reactions

Most common adverse reactions (≥3%) are injection site reactions, constipation, fatigue, headache, diarrhea, abdominal pain, insomnia, dyspepsia, dizziness, asthenia, and gastroesophageal reflux.

Report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Report side effects to Heron at 1-844-437-6611.

Please see full Prescribing Information, including Medication Guide.

References:

Gabrail, et al. Cancer Manag Res. 2015.
Data on File [C2006-01]. Heron Therapeutics, Inc.
Data on File [C2013-01]. Heron Therapeutics, Inc.
SUSTOL [prescribing information]. Heron Therapeutics, Inc., 2023.
Schnadig, et al. Future Oncol. 2016.
Aloxi [prescribing information]. Helsinn Therapeutics (U.S.), Inc., 2020.
Zofran [prescribing information]. GlaxoSmithKline, 2017.
Kytril [prescribing information]. Genentech, Inc., 2011.
Sancuso [prescribing information]. Kyowa Kirin, Inc., 2022.
Anzemet [prescribing information]. Validus Pharmaceuticals LLC, 2021.
Data on File [Summary of Clinical Safety]. Heron Therapeutics, Inc.
Smith, et al. Cancer Nurs. 2019.